Y-90 beads plus chemo for liver-only colorectal cancer
Part of Cancer clinical trials.
This trial tests whether adding radioactive Y-90 microspheres (tiny beads that deliver radiation directly to liver tumors) to standard chemo (FOLFIRI and bevacizumab) can help people with advanced colorectal cancer that has spread only to one lobe of the liver, when the first treatment stopped working. The goal is to slow down tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your colorectal cancer has spread to the liver, but only to one lobe of the liver, and the original colon or rectal tumor has been removed.
- Your liver tumors got worse after your first treatment, and you are now scheduled to receive a chemotherapy combo called FOLFIRI plus bevacizumab.
- Your cancer has a specific genetic change called a KRAS mutation.
- You have good performance status (ECOG 0 or 1) – meaning you can carry out daily activities with little or no help.
- Your liver and kidney function are within safe limits as shown by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study observes people with colorectal cancer that has spread to the liver and cannot be removed by surgery. It looks at how well a treatment called SIR-Spheres (tiny radioactive beads) works after other treatments have failed.
This trial tests a targeted radiation treatment (Y-90 radioembolization) given before surgery for colorectal cancer that has spread to the liver. The goal is to shrink liver tumors enough to make them removable and improve the chance of a successful surgery.
This trial tests a radiation treatment called Y-90 given before liver surgery for colorectal cancer that has spread to the liver. The goal is to help the liver grow enough for safer, curative surgery, either right away or as part of a two-step operation.
This trial tests a combination of targeted radiation (Y-90), chemotherapy (capecitabine), and immunotherapy (atezolizumab) for people with colorectal cancer that has spread mainly to the liver and is no longer responding to at least two prior treatments. The goal is to see if this combination can shrink tumors or slow the disease.
This trial tests a treatment called Y-90 radioembolization (SIRT) for people with liver cancer that is too large to be removed surgically. The treatment delivers tiny radioactive beads directly to the tumor through the liver's blood supply, which may shrink the tumor and improve outcomes.
This trial tests combining Yttrium-90 microspheres (tiny radioactive beads delivered into the liver), immunotherapy (drugs that help your immune system fight cancer), and anti-angiogenesis drugs (medicines that block blood supply to tumors) followed by a liver-directed chemotherapy infusion. It is designed for people with hepatocellular carcinoma (liver cancer) that cannot be removed with surgery yet may become operable after this treatment.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.